After the outbreak: how the British Columbia commercial poultry industry recovered after H7N3 HPAI.

Avian Dis

Animal Health Centre, BC Ministry of Agriculture & Lands, 1767 Angus Campbell Road, Abbotsford, British Columbia, Canada V3G 2M3.

Published: March 2007

In spring 2004, an outbreak of highly pathogenic avian influenza (HPAI), subtype H7N3, occurred in the Fraser Valley of British Columbia, Canada. The active outbreak lasted more than 90 days; 42 commercial poultry farms were identified as infected premises, and more than 17 million birds were culled. Through the depopulation of HPAI-positive farms and the strategic depopulation of adjacent test-negative farms, a total of 410 commercial poultry farms were emptied. The goals for the commercial poultry industry were to expedite restocking, reduce nonproductive downtime, negotiate equitable financial compensation, review and restructure emergency disease response plans, and identify and implement mitigation strategies. After the outbreak, multijurisdictional reviews identified the strengths and weaknesses of the outbreak control strategy. Lessons learned were incorporated into current emergency disease response protocols for both industry and government. The industry-led challenge to initial compensation values, especially for specialty poultry and breeder birds, resulted in a review of the federal Health of Animals Act. The British Columbia poultry industry, in collaboration with the British Columbia Ministry of Agriculture and Lands, developed an Enhanced Biosecurity Initiative that included the identification of mandatory on-farm biosecurity standards for commercial producers, an educational biosecurity self-assessment guide, and provisions for a producer self-quarantine to be enacted upon the first suspicion of disease.

Download full-text PDF

Source
http://dx.doi.org/10.1637/7627-042706R.1DOI Listing

Publication Analysis

Top Keywords

british columbia
16
commercial poultry
16
poultry industry
12
poultry farms
8
emergency disease
8
disease response
8
poultry
6
outbreak
5
commercial
5
outbreak british
4

Similar Publications

The cold tolerance of the terrestrial slug, Ambigolimax valentianus.

J Comp Physiol A Neuroethol Sens Neural Behav Physiol

January 2025

Department of Zoology, University of British Columbia, Vancouver, BC, Canada.

Terrestrial molluscs living in temperate and polar environments must contend with cold winter temperatures. However, the physiological mechanisms underlying the survival of terrestrial molluscs in cold environments and the strategies employed by them are poorly understood. Here we investigated the cold tolerance of Ambigolimax valentianus, an invasive, terrestrial slug that has established populations in Japan, Canada, and Europe.

View Article and Find Full Text PDF

Left atrial appendage occlusion (LAAO) has become an important therapeutic target for stroke prevention in patients with nonvalvular atrial fibrillation. Over the past 2 decades, several advancements in LAAO devices (percutaneous and surgical) have been made for stroke prevention and arrhythmia therapy. However, there are several unanswered questions regarding optimal patient selection, the preferred LAAO approach and device, the management of periprocedural and postprocedural complications, including pericardial effusion, device-related thrombus, and device leaks.

View Article and Find Full Text PDF

Purpose: 1) To identify outcome measures used in support programs designed to enhance functioning in autistic children and adolescents, and 2) To map the content of these measures to the domains of the International Classification of Functioning, Disability and Health (ICF).

Methods: A systematic review was conducted. Searches were performed in Medline/PubMed, EMBASE and Virtual Health Library databases, with no restrictions imposed regarding language or year of publication.

View Article and Find Full Text PDF

Background/objectives: Pembrolizumab monotherapy is approved in Canada for first-line treatment of advanced NSCLC with PD-L1 ≥ 50% and no EGFR/ALK aberrations. However, approximately 55% of these patients do not respond to pembrolizumab, underscoring the need for the early intervention of non-responders to optimize treatment strategies. Distinguishing the 55% sub-cohort prior to treatment is a real-world dilemma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!